Clinical Trials Logo
  1. Home
  2. Overactive Bladder
  3. NCT04309890
  4. Details
NCT04309890 Clinical Trial

Arabic Translation and Validation of the (Overactive Bladder Symptom Score) OABSS

Overactive Bladder Clinical Trial

Official title:
Validating 7-items Overactive Bladder Symptom Score (OABSS) Through Arabic Linguistic Version

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04309890
Other study ID # Arabic OABSS- 7 items
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 1, 2019
Est. completion date June 30, 2019

Study information
Verified date March 2020
Source Mutah University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The English version of the Overactive Bladder Symptom Score (OABSS) questionnaire was translated to Arabic language. The questionnaire was validated by comparing the response to the questionnaire in a patient with Overactive Bladder (OAB) before and after providing treatment with antimuscarinics.

Recruitment information / eligibility
Status Completed
Enrollment 235
Est. completion date June 30, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

- More than 20 years

- Had three months history of overactive bladder symptoms (urgency with or without incontinence and associated with frequency and nocturia).

Exclusion Criteria:

- Active urinary tract infection.

- Predominant symptoms of urinary stress incontinence;

- Diabetes mellitus;

- Previous abdominal and pelvic (urological or gynecological gastrointestinal) surgery;

- Previous neurological disease.

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Arabic version of the Overactive Bladder Symptom Score Questionnaire
All enrolled patients were asked to complete the Arabic OABSS questionnaire in its final edition before and three months after treatment with Solfinasin 5 mg once daily

Locations
Country Name City State
Jordan Mu'tah University Karak

Sponsors (1)
Lead Sponsor Collaborator
Mutah University

Country where clinical trial is conducted

Jordan, 

Outcome
Type Measure Description Time frame Safety issue
Primary development and validation of Arabic version of the Overactive Bladder Symptom Score (OABSS) questionnaire 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04578899 - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" N/A
Active, not recruiting NCT03556891 - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence N/A
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT03727711 - TPTNS: Home vs Hospital Treatment for Overactive Bladder N/A
Completed NCT00768521 - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) Phase 1
Completed NCT03625843 - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing N/A
Completed NCT02211846 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Phase 1
Completed NCT02857816 - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB N/A
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT02202031 - Controlling Urgency Through Relaxation Exercises N/A
Withdrawn NCT02320201 - Foot Neuromodulation for Overactive Bladder in Children N/A
Completed NCT01458197 - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. Phase 2
Not yet recruiting NCT01409512 - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder N/A
Not yet recruiting NCT01423838 - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Phase 4
Completed NCT01437670 - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin N/A
Terminated NCT01758848 - Physical Therapy for Overactive Bladder N/A
Withdrawn NCT01210859 - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents N/A
Completed NCT00910520 - Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Phase 3